Target type: biologicalprocess
The process in which the anatomical structures of veins of the heart are generated and organized. [GOC:mtg_heart]
Coronary vein morphogenesis is a complex and intricate process that begins during early embryonic development and continues throughout fetal life. It involves the coordinated interaction of multiple cellular and molecular signaling pathways to establish the intricate network of coronary veins that supply blood to the heart.
The process begins with the formation of the heart tube, which is initially a simple, tubular structure. As the heart tube develops, it undergoes a series of looping and folding events that give rise to the four chambers of the heart. Simultaneously, a network of endothelial cells begins to form within the heart tube, giving rise to the primitive coronary vasculature.
One of the key factors in coronary vein morphogenesis is the expression of vascular endothelial growth factor (VEGF). VEGF is a potent angiogenic factor that stimulates the growth and differentiation of endothelial cells. During early heart development, VEGF is expressed in the myocardium, the muscular wall of the heart. This expression pattern guides the formation of the coronary arteries, which arise from the aortic root.
However, the development of the coronary veins is more complex. They arise from the primitive venous system that drains the heart tube. As the heart tube undergoes looping and folding, the primitive veins become incorporated into the developing heart, forming the coronary sinus. This process is regulated by a combination of signaling pathways, including Notch, Wnt, and Hedgehog.
The coronary veins are further elaborated through a process of sprouting angiogenesis. This process involves the extension of new blood vessels from existing ones. The sprouts are guided by chemotactic gradients of growth factors, such as VEGF and fibroblast growth factor (FGF). As the sprouts grow, they are stabilized by the deposition of extracellular matrix components, such as collagen and laminin.
The development of the coronary veins is also influenced by the surrounding myocardium. The cardiomyocytes, the muscle cells of the heart, secrete a number of factors that regulate vascular growth and differentiation. These factors include platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta), and angiopoietins.
The coronary veins continue to mature and remodel throughout fetal life. This process involves the formation of new vessels, the expansion of existing vessels, and the regression of unnecessary vessels. These changes are driven by the changing demands of the developing heart.
At birth, the coronary vein network is fully formed and functional. However, the veins continue to undergo subtle remodeling throughout life, responding to changes in cardiac function and blood flow.
Dysregulation of coronary vein morphogenesis can lead to a number of congenital heart defects, including coronary artery anomalies, coronary vein malformations, and coronary sinus defects. These defects can result in compromised blood flow to the heart, leading to heart failure and other complications.
In conclusion, coronary vein morphogenesis is a complex and tightly regulated process that involves the interplay of multiple signaling pathways and cellular interactions. It is essential for the normal development of the coronary vasculature and the healthy function of the heart.'
"
Protein | Definition | Taxonomy |
---|---|---|
Neurogenic locus notch homolog protein 1 | A neurogenic locus notch homolog protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P46531] | Homo sapiens (human) |
Vascular endothelial growth factor A | A vascular endothelial growth factor A, long form that is encoded in the genome of human. [PRO:DNx, UniProtKB:P15692] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
4-phenylphenol | 4-phenylphenol: RN given refers to cpd without isomeric designation biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4. | hydroxybiphenyls | |
calotropin | calotropin: structure in first source | cardenolide glycoside | |
4-phenylbenzoic acid | 4-phenylbenzoic acid: RN given refers to 4-carboxylic cpd | ||
amentoflavone | biflavonoid; hydroxyflavone; ring assembly | angiogenesis inhibitor; antiviral agent; cathepsin B inhibitor; P450 inhibitor; plant metabolite | |
proanthocyanidin a1 | procyanidin A1: from aqueous extract of peanut skin; structure in first source | flavonoid oligomer | |
phosphomannopentaose sulfate | phosphomannopentaose sulfate: structure in first source |